LXRX - LEXICON PHARMACEUTICALS, INC.
IEX Last Trade
0.7427
0.011 1.535%
Share volume: 39,421
Last Updated: Thu 26 Dec 2024 08:29:51 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.73
0.01
1.56%
Fundamental analysis
13%
Profitability
0%
Dept financing
11%
Liquidity
75%
Performance
10%
Performance
5 Days
-8.37%
1 Month
-7.61%
3 Months
-50.79%
6 Months
-54.89%
1 Year
-46.26%
2 Year
-58.59%
Key data
Stock price
$0.74
DAY RANGE
$0.70 - $0.74
52 WEEK RANGE
$0.70 - $3.73
52 WEEK CHANGE
-$50.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Lonnel Coats
Region: US
Website: lexpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lexpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.
Recent news